Long-term assessment of acromegaly treatment patterns and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the treatment patterns and clinical outcomes of patients with acromegaly in China. It will collect medical information without interfering with ongoing treatments, focusing on the effectiveness and economic impact of various treatment modalities. Patients will be assigned unique identification numbers to maintain confidentiality while allowing for data extraction from their medical records. The study adheres to international guidelines for good clinical practice and local privacy laws.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be able and willing to sign the informed consent form (ICF)
2. Male, female, age 18-75 years old (including 18 years old and 75 years old).
3. Compliance with acromegaly diagnostic criteria:

   * At least one laboratory or medical record shows that the patient is random GH ≥ 2.5 μg / L
   * At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor

Exclusion Criteria:

1. Ectopic secretion of GH or pituitary cancer
2. The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue.
3. Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study.
4. Be a patient who, in the judgement of the Investigator, would be inappropriate for enrollment in this study

Where it's running

• China Acromegaly Organization
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTQ6179 tablets first-in-human test in healthy adults

  This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.

  Recruiting Phase 1 Nanjing Chia-tai Tianqing Pharmaceutical · Beijing · NCT07909837

• Test MAR002 for acromegaly in adults on or off medical therapy

  This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.

  Recruiting at 3 sites Phase 2 Marea Therapeutics · Phoenix, Arizona and 2 other locations · NCT07641179

• Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness

  This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.

  Recruiting at 4 sites Camurus AB · Aachen and 6 other locations · NCT07583563

• MAR002 in healthy men

  This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.

  Recruiting Phase 1 Marea Therapeutics · Tempe, Arizona · NCT07195175

• Pasireotide LAR and bone health in adults with acromegaly

  This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07179926

• Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs

  This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.

  Recruiting at 72 sites Phase 3 Debiopharm International SA · Los Angeles, California and 73 other locations · NCT06930625

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.